MinorEssential amino acid×Selective serotonin reuptake inhibitors (SSRIs)
Updated · Methodology
Mechanism
Sertraline is metabolised in the liver by several pathways, including CYP3A4, CYP2C19 and CYP2B6, and has an elimination half-life of about 26 hours (Besitran SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). L-lysine is an essential amino acid. No medicine in Spain contains it as the active substance, and it is sold as a food supplement. In healthy women and people with osteoporosis, lysine 400–800 mg increased intestinal calcium absorption and reduced urinary calcium loss (Civitelli et al., 1992). This combination has not been studied, and no mechanism by which lysine would change sertraline levels or effects is known. The sertraline SmPC does not mention lysine (Besitran SmPC, AEMPS, section 4.5).
Symptoms
No symptoms caused by this combination have been described. Sertraline can lower blood sodium and increase the risk of bleeding, especially with drugs that affect platelet function (Besitran SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4). In a systematic review of 71 studies with 3357 participants, lysine's adverse events were mainly gastrointestinal, and their risk did not differ significantly from control (Hayamizu et al., 2020).
Management
The combination can be used and no dose change is needed. There are no data on an interaction, and no mechanism that would cause one is known (Besitran SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The review authors set a provisional no-observed-adverse-effect level of 6 g of lysine a day in healthy adults (Hayamizu et al., 2020).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Sertralina (Besitran 50 mg) (nº registro 59717), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 59717, revisión 08/2025, secciones 4.4 y 4.5
- Nutrition: Dietary L-lysine and calcium metabolism in humans (1992)– Civitelli R, et al. Nutrition. 1992;8(6):400-5. PMID 1486246
- The Journal of nutrition: Comprehensive Safety Assessment of l-Lysine Supplementation from Clinical Studies: A Systematic Review (2020)– Hayamizu K, Oshima I, Nakano M. J Nutr. 2020;150(Suppl 1):2561S-2569S. PMID 33000161